489,485 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Alta Partners Management Company L.P.

Alta Partners Management Company L.P. purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 489,485 shares of the company's stock, valued at approximately $3,593,000. Vir Biotechnology accounts for about 5.7% of Alta Partners Management Company L.P.'s portfolio, making the stock its 2nd largest position. Alta Partners Management Company L.P. owned 0.36% of Vir Biotechnology as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of VIR. Blue Trust Inc. increased its holdings in Vir Biotechnology by 143.5% in the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock worth $30,000 after acquiring an additional 2,351 shares in the last quarter. KBC Group NV boosted its position in shares of Vir Biotechnology by 136.5% in the fourth quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after purchasing an additional 5,177 shares during the period. CIBC Asset Management Inc purchased a new stake in shares of Vir Biotechnology in the fourth quarter worth $74,000. Captrust Financial Advisors bought a new stake in shares of Vir Biotechnology during the 3rd quarter valued at $118,000. Finally, Quarry LP lifted its stake in shares of Vir Biotechnology by 901.8% during the 3rd quarter. Quarry LP now owns 17,000 shares of the company's stock valued at $127,000 after buying an additional 15,303 shares in the last quarter. Hedge funds and other institutional investors own 65.32% of the company's stock.

Vir Biotechnology Trading Up 0.2 %

VIR traded up $0.02 during trading hours on Wednesday, hitting $8.22. The company's stock had a trading volume of 1,331,603 shares, compared to its average volume of 2,418,664. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -2.10 and a beta of 0.64. The business's 50-day moving average price is $9.48 and its 200-day moving average price is $8.49. Vir Biotechnology, Inc. has a 12 month low of $6.56 and a 12 month high of $14.45.

Remove Ads

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm had revenue of $12.37 million for the quarter, compared to analysts' expectations of $8.14 million. On average, analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Insider Buying and Selling at Vir Biotechnology

In related news, Director George A. Scangos sold 10,964 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total transaction of $107,556.84. Following the transaction, the director now directly owns 708,295 shares in the company, valued at approximately $6,948,373.95. This represents a 1.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Verneuil Vanina De sold 7,373 shares of the firm's stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the sale, the executive vice president now directly owns 79,460 shares of the company's stock, valued at approximately $726,264.40. The trade was a 8.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,859 shares of company stock worth $326,458 over the last ninety days. Company insiders own 15.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. increased their price target on Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research note on Thursday, January 9th. Leerink Partners lifted their target price on Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. HC Wainwright restated a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, February 28th. Needham & Company LLC reissued a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a report on Thursday, February 27th. Finally, Morgan Stanley raised shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $35.67.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).